title: Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one.
abstract: Transgenic mice with both alleles of the p53 tumor suppressor gene product 'knocked out' by gene targeting are susceptible to early development of tumors, chiefly lymphomas and sarcomas. Compared with the control group, administration of dehydroepiandrosterone (DHEA) at 0.3% of the diet to male p53-deficient mice extended their lifespan by delaying death due to neoplasms (from 105 to 166 days on study, P = 0.002), primarily by suppressing lymphoblastic lymphoma (from 45 to 6% of neoplastic deaths, P = 0.010). Treatment with a synthetic DHEA analog, 16alpha-fluoro-5-androsten-17-one (compound 8354), at 0.15% of the diet also increased lifespan, to 140 days for mice that developed tumors (P = 0.037). The effects of these steroids on lifespan and tumor development did not appear to be strongly related to inhibition of food consumption and weight gain, in that a group pair-fed with control diet to the reduced food consumption of the DHEA-treated group developed and died of the same types of neoplasms at the same rate as the controls fed ad libitum. The chemopreventive effect of these steroids has been proposed to be due to suppression of DNA synthesis by inhibition of glucose 6-phosphate dehydrogenase, the rate-limiting enzyme of the pentose phosphate pathway. Although DHEA and its analog are strong non-competitive inhibitors of this enzyme in vitro, treatment with DHEA did not deplete cellular nucleotide pools in the liver, as would have been predicted. The chemopreventive effect of DHEA in this model may be due to steroid-induced thymic atrophy and suppression of T cell lymphoma, permitting these mice to survive long enough to develop tumors with longer latency.
authors.affiliation: Laboratory of Nutritional and Molecular Regulation, SAIC, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702-1201, USA.
authors.forename: S N
authors.initials: SN
authors.lastname: Perkins
authors.forename: S D
authors.initials: SD
authors.lastname: Hursting
authors.forename: D C
authors.initials: DC
authors.lastname: Haines
authors.forename: S J
authors.initials: SJ
authors.lastname: James
authors.forename: B J
authors.initials: BJ
authors.lastname: Miller
authors.forename: J M
authors.initials: JM
authors.lastname: Phang
mesh_terms: D000736:Androstenes / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D003687:Dehydroepiandrosterone / Q000494:pharmacology*; D016158:Genes, p53; D008099:Liver / Q000378:metabolism; D008136:Longevity / Q000187:drug effects; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009711:Nucleotides / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000209:etiology; D016019:Survival Analysis
chemical_list: D000736:Androstenes; D000970:Antineoplastic Agents; D009711:Nucleotides; C066783:16-fluoro-5-androsten-17-one; D003687:Dehydroepiandrosterone